健世科技-B(09877)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09877 健世科技-B

已收盘 09-30 16:08:26

7.395

+0.010

+0.14%

最高7.645	最低6.950	成交量2.22万
今开7.385	昨收7.385	日振幅9.41%
总市值30.85亿	流通市值22.95亿	总股本4.17亿
成交额16.24万	换手率0.01%	流通股本3.10亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09877","market":"HK","secType":"STK","nameCN":"健世科技-B","latestPrice":7.395,"timestamp":1790755706237,"preClose":7.385,"halted":0,"volume":22200,"delay":0,"changeRate":0.0013540961408259698,"floatShares":310306209,"shares":417167290,"eps":-0.7487138283849099,"marketStatus":"已收盘","change":0.01,"latestTime":"09-30 16:08:26","open":7.385,"high":7.645,"low":6.95,"amount":162422,"amplitude":0.09411,"askPrice":7.395,"askSize":6000,"bidPrice":7.055,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-0.4057303633324964,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1790904600000},"marketStatusCode":5,"adr":0,"listingDate":1665331200000,"exchange":"SEHK","adjPreClose":7.385,"openAndCloseTimeList":[[1790731800000,1790740800000],[1790744400000,1790755200000]],"volumeRatio":1.390977,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09877","defaultTab":"news","newsList":[{"id":"2671046213","title":"从JensClip获批看健世科技：产品补位、渠道复用与全球化","url":"https://stock-news.laohu8.com/highlight/detail?id=2671046213","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671046213?lang=zh_cn&edition=full","pubTime":"2026-09-29 18:31","pubTimestamp":1790677897,"startTime":"0","endTime":"0","summary":"经导管介入二尖瓣修复（TMVr）系统JensClip正式获中国国家药品监督管理局（NMPA）批准上市","market":"sg","thumbnail":"https://img7.gelonghui.com/column/2.png?guru_height=540&guru_width=375","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2.png?guru_height=540&guru_width=375"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/6848336","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["09877","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111217767","title":"健世科技-B2026年上半年营收64.13百万元，经调整净亏损24.59百万元","url":"https://stock-news.laohu8.com/highlight/detail?id=1111217767","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1111217767?lang=zh_cn&edition=full","pubTime":"2026-09-29 18:06","pubTimestamp":1790676407,"startTime":"0","endTime":"0","summary":"截至2026年6月30日止六个月，健世科技-B实现营收64.13百万元，同比上年同期的13.43百万元增长377.7%。期内经调整净亏损24.59百万元，同比上年同期的91.76百万元大幅收窄73.2%。经营活动所用现金流量净额为74.81百万元，较上年同期的92.74百万元有一定改善。报告期内，中国内地收入34.65百万元，海外收入29.49百万元，占总收入46.0%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"健世科技-B2026年上半年营收64.13百万元，经调整净亏损24.59百万元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131211414","title":"健世科技-B宣布Jensclip经导管瓣膜修复系统获NMPA注册批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1131211414","media":"投资观察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1131211414?lang=zh_cn&edition=full","pubTime":"2026-09-23 00:25","pubTimestamp":1790094326,"startTime":"0","endTime":"0","summary":"9月22日（路透社）——健世科技-B（9877.HK）宣布，其Jensclip经导管瓣膜修复系统已正式获得国家药品监督管理局（NMPA）的注册批准。该公司正积极推动Jensclip在中国及其他市场的商业化进程。更多关于9877.HK的公司详情，请参阅后续报道。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09877","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139928937","title":"健世科技-B(09877)自主研发JensClip获NMPA注册批准并启动国内外商业化","url":"https://stock-news.laohu8.com/highlight/detail?id=1139928937","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1139928937?lang=zh_cn&edition=full","pubTime":"2026-09-22 19:32","pubTimestamp":1790076728,"startTime":"0","endTime":"0","summary":"2026年9月22日，健世科技-B公告称，公司自主开发的经导管二尖瓣夹及输送系统JensClip Transcatheter Valve Repaire System已获得国家药品监督管理局的注册批准。\\n\\n公司表示，已着手推进JensClip在中国大陆市场的商业化，并积极推动CE MDR注册等海外审批及商业化进程。此外，JensClip已在海外开展同情治疗及救治手术，进展顺利。\\n\\n随着JensClip取得注册批准，健世科技-B的产品组合已覆盖主动脉瓣、二尖瓣及三尖瓣等结构性心脏病介入治疗三大瓣膜领域。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146036600","title":"健世科技-B：加速推进Jensclip在中国及全球市场的商业化布局","url":"https://stock-news.laohu8.com/highlight/detail?id=1146036600","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146036600?lang=zh_cn&edition=full","pubTime":"2026-09-22 19:29","pubTimestamp":1790076548,"startTime":"0","endTime":"0","summary":"健世科技-B（JENSCARE-B）正全力推动其核心产品Jensclip在中国及其他海外市场的商业化进程。公司当前战略聚焦于这一关键产品的市场落地，力求在国内外多个区域实现规模化应用。此举标志着健世科技在结构性心脏病介入领域的布局正从研发阶段向商业化阶段全面转型。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09877","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101539464","title":"健世科技-B：Jensclip经导管瓣膜修复系统获国家药监局注册批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1101539464","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1101539464?lang=zh_cn&edition=full","pubTime":"2026-09-22 19:28","pubTimestamp":1790076490,"startTime":"0","endTime":"0","summary":"健世科技-B近日宣布，其自主研发的Jensclip经导管瓣膜修复系统已成功获得国家药品监督管理局的注册批准。Jensclip系统的获批，不仅丰富了健世科技的产品管线，也为广大患者带来了新的治疗选择。据悉，该系统旨在通过微创方式修复病变的瓣膜，从而避免传统开胸手术带来的创伤。健世科技此次获批的Jensclip系统，有望在未来市场竞争中占据有利位置，进一步巩固其在行业内的技术领先地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09877","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159509344","title":"健世科技-B宣布LuX-Valve Plus获得香港卫生署批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1159509344","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159509344?lang=zh_cn&edition=full","pubTime":"2026-09-04 22:50","pubTimestamp":1788533432,"startTime":"0","endTime":"0","summary":"2026年9月4日，健世科技-B发布自愿公告称，其经导管三尖瓣置换系统LuX-Valve Plus已于近日取得中华人民共和国香港特别行政区卫生署的批准，公司正积极推进该产品在中国香港地区的商业化。公告显示，LuX-Valve Plus是全球第二款获批的经导管原位三尖瓣置换产品，已先后在欧洲、中东、亚太等多个国家及地区获得注册批准。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124497493","title":"健世科技-B 8月股份变动月报表：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1124497493","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124497493?lang=zh_cn&edition=full","pubTime":"2026-09-04 17:15","pubTimestamp":1788513349,"startTime":"0","endTime":"0","summary":"宁波健世科技股份有限公司于2026年9月4日发布2026年8月股份变动月报表。报告期为2026年8月1日至2026年8月31日。公告显示，公司已发行股份和注册股本在报告期内均保持稳定，未发生新增发行、购回、注销或库存股变动。公司同步披露，在报告期内未有期权、可转换债券或其他协议引发的股份发行或变动。截至8月底，公司股本结构保持稳定，且不存在库价回购或股份回购的相关事宜。公告由公司秘书李远源正式签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664764958","title":"营收爆发式增长印证商业化拐点 健世科技-B（09877）以创新实力参与全球竞争 稳步提升市场地位","url":"https://stock-news.laohu8.com/highlight/detail?id=2664764958","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664764958?lang=zh_cn&edition=full","pubTime":"2026-09-03 18:55","pubTimestamp":1788432954,"startTime":"0","endTime":"0","summary":"8月31日，健世科技交出了一份极具里程碑意义的中期成绩单。该试验设计不仅体现了FDA对产品差异化优势的认可，更意味着健世科技敢于以国际最高循证标准直面全球行业龙头，为美国市场准入构筑坚实的证据壁垒。简言之，健世科技的战略价值并非简单输出产品，而是以全球最高监管标准重构临床证据体系与市场准入路径，赋予其全球化成长更高的可持续性与竞争壁垒。其NMPA注册申请目前处于审评关键阶段，有望尽快实现国内商业化。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491664.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"营收爆发式增长印证商业化拐点 健世科技-B（09877）以创新实力参与全球竞争 稳步提升市场地位","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192797384","title":"健世科技-B2026年中期营收6,413.10万元，经调整净亏损2,458.60万元","url":"https://stock-news.laohu8.com/highlight/detail?id=1192797384","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192797384?lang=zh_cn&edition=full","pubTime":"2026-08-31 21:07","pubTimestamp":1788181657,"startTime":"0","endTime":"0","summary":"根据公司公告，健世科技-B在2026年上半年实现营收64,131千元，折合约6,413.10万元，同比增长377.7%。期内整体毛利率为86.5%。同期经调整非IFRS准则口径下的期内净亏损2,458.60万元，较去年同期的9,175.60万元显著收窄73.2%。在主要费用方面，2026年上半年研发投入为52,576千元，同比下降40.8%，研发投入占收入的比重约82%。行政开支为33,626千元，同比下降约41.5%，同样源于股权激励支出规模减少等因素。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"健世科技-B2026年中期营收6,413.10万元，经调整净亏损2,458.60万元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156105519","title":"健世科技-B（09877）修订与琳盛医疗器械配件采购协议 2026及2027年度上限双双上调","url":"https://stock-news.laohu8.com/highlight/detail?id=1156105519","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1156105519?lang=zh_cn&edition=full","pubTime":"2026-08-31 21:07","pubTimestamp":1788181652,"startTime":"0","endTime":"0","summary":"2026年8月31日，健世科技-B发布公告称，公司已与关联方宁波琳盛高分子材料有限公司签署《医疗器械配件采购协议之补充协议》，上调截至2026年及2027年12月31日止两个年度的采购年度上限。根据补充协议，原有年度上限分别为截至2026年12月31日止年度人民币2,338,000元及截至2027年12月31日止年度人民币2,695,000元。截至2026年7月31日，协议项下实际交易金额为人民币2,021,000元，约占2026年度原有上限的86.4%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160129842","title":"健世科技-B发布董事会会议通告 拟于8月31日审议2026年中期业绩及分红方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1160129842","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1160129842?lang=zh_cn&edition=full","pubTime":"2026-08-19 21:25","pubTimestamp":1787145950,"startTime":"0","endTime":"0","summary":"健世科技-B（09877）8月19日公告称，公司董事会会议拟于2026年8月31日（星期一）举行。届时，董事会将审议并批准本集团截至2026年6月30日止六个月的中期业绩及其发布事宜，并考虑建议派发中期股息（如有），同时处理其他相关事项。\n公告显示，目前公司董事会成员包括：执行董事兼首席执行官潘斐；非执行董事吕世文、TAN Ching、郑嘉齐、谢优佩及陈新星；独立非执行董事林寿康、杜季柳及梅乐和。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178959472","title":"健世科技-B（09877）：预计2026年上半年收入约63至65百万元 同比增385%至400%","url":"https://stock-news.laohu8.com/highlight/detail?id=1178959472","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1178959472?lang=zh_cn&edition=full","pubTime":"2026-08-10 12:21","pubTimestamp":1786335706,"startTime":"0","endTime":"0","summary":"智通财经讯，健世科技-B 8月10日公告披露2026年中期收入预告。根据截至2026年6月30日止六个月的最新未经审核综合管理账目及其他可得资料，公司预计：。— 报告期内实现收入人民币约63至65百万元，同比增加人民币50至52百万元，增幅约为385%至400%。— 综合计算，上述两项合计收入预计约72至76百万元，同比增加人民币47至51百万元，增幅约为188%至204%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658602582","title":"健世科技-B(09877)预计中期收入同比增加385%至400%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658602582","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658602582?lang=zh_cn&edition=full","pubTime":"2026-08-10 12:17","pubTimestamp":1786335445,"startTime":"0","endTime":"0","summary":"智通财经APP讯，健世科技-B 发布公告，集团预期截至2026年6月30日止六个月实现收入人民币约6300万元至6500万元，同比增加385%至400%。其他收入及收益人民币约900万至1100万元，共计人民币约7200万至7600万元，与上年同期相比，将增加人民币4700万元至5100万元，同比增加188%至204%。报告期间业绩增长的主要原因包括：1.集团经导管人工主动脉瓣膜系统Ken-Valve商业化持续实现稳健收入增长。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477862.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"健世科技-B(09877)预计中期收入同比增加385%至400%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1100","09877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100623260","title":"健世科技-B2026年7月股份变动月报：股本保持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1100623260","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100623260?lang=zh_cn&edition=full","pubTime":"2026-08-06 17:16","pubTimestamp":1786007807,"startTime":"0","endTime":"0","summary":"宁波健世科技股份有限公司（“健世科技-B”，股票代码：09877）于2026年8月6日发布2026年7月股份变动月报，报告期覆盖2026年7月1日至7月31日。\n公告显示，普通股H股上月底及本月底均为310,306,209股，未出现新增发行、回购或注销等变化；非上市普通股维持106,861,081股，总注册股本417,167,290元人民币保持不变。公司同时确认，截至本月底满足最低公众持股量要求，其H股公众持股比例为17.32%，无任何股份期权、权证、可换股票据或其他股份变动安排。公告由公司秘书李远源签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156630375","title":"健世科技-B公布LuX-Valve Plus在美国关键性注册临床试验完成首批植入","url":"https://stock-news.laohu8.com/highlight/detail?id=1156630375","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1156630375?lang=zh_cn&edition=full","pubTime":"2026-07-16 12:26","pubTimestamp":1784175965,"startTime":"0","endTime":"0","summary":"健世科技-B7月16日自愿公告称，公司自主研发的经导管三尖瓣置换系统LuX-Valve Plus已在美国食品及药品监督管理局批准的关键性注册临床试验中完成首批受试者植入。公司表示，基于LuX-Valve Plus的设计优势及临床表现，该试验获得全球多中心积极参与，将持续加速推进试验进程。健世科技-B提醒投资者，根据香港联合交易所有限公司证券上市规则第18A.05条，概不保证LuX-Valve Plus最终能成功推向市场及/或商业化。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651413533","title":"健世科技-B(09877.HK)：经导管三尖瓣置换系统LuX-ValvePlus完成FDA批准的关键性注册临床试验(Pivotal Trial)的首批受试者植入","url":"https://stock-news.laohu8.com/highlight/detail?id=2651413533","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651413533?lang=zh_cn&edition=full","pubTime":"2026-07-16 12:23","pubTimestamp":1784175829,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09877","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649995181","title":"港股异动 | 健世科技-B(09877)涨超7% 经导管三尖瓣置换系统取得欧盟MDR CE认证","url":"https://stock-news.laohu8.com/highlight/detail?id=2649995181","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649995181?lang=zh_cn&edition=full","pubTime":"2026-07-08 09:54","pubTimestamp":1783475658,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，健世科技-B涨超7%，截至发稿，涨7.46%，报8.21港元，成交额125.77万港元。消息面上，健世科技今早公布，近日，集团自主研发的经导管三尖瓣置换系统 LuX-Valve Plus取得欧盟MDR CE认证，达成公司国际化战略的重要里程碑。公司表示正持续快速推进LuX-Valve Plus在欧洲以及全球的商业化进程，实现公司长期国际化战略目标。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1464508.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["PSCM","BK4109","KCAI","BK1100","FSXEmain","VXUS","FESXmain","BK4588","CE","09877","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649518139","title":"港股异动 | 健世科技-B(09877.HK)涨超7% 经导管三尖瓣置换系统取得欧盟MDR CE认证","url":"https://stock-news.laohu8.com/highlight/detail?id=2649518139","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649518139?lang=zh_cn&edition=full","pubTime":"2026-07-08 09:54","pubTimestamp":1783475658,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1100","09877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649955634","title":"健世科技-B(09877)：经导管三尖瓣置换系统LuX-Valve Plus取得欧盟MDR CE认证","url":"https://stock-news.laohu8.com/highlight/detail?id=2649955634","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649955634?lang=zh_cn&edition=full","pubTime":"2026-07-08 08:02","pubTimestamp":1783468948,"startTime":"0","endTime":"0","summary":"智通财经APP讯，健世科技-B 发布公告，近日，集团自主研发的经导管三尖瓣置换系统 LuX-Valve Plus取得欧盟MDR CE认证，达成公司国际化战略的重要里程碑。LuX-Valve Plus是全球第二款获批的经导管塬位三尖瓣置换产品。公司正持续快速推进LuX-Valve Plus在欧洲以及全球的商业化进程，实现公司长期国际化战略目标。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1464458.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["CE","09877","PSCM","BK4585","FSXEmain","BK4109","BK4588","BK1100","FESXmain"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.jenscare.com","stockEarnings":[{"period":"1week","weight":0.0401},{"period":"1month","weight":0.0221},{"period":"3month","weight":0.0186},{"period":"6month","weight":-0.2177},{"period":"1year","weight":-0.1712},{"period":"ytd","weight":-0.1702}],"compareEarnings":[{"period":"1week","weight":-0.0225},{"period":"1month","weight":-0.0415},{"period":"3month","weight":0.0718},{"period":"6month","weight":-0.0236},{"period":"1year","weight":-0.0789},{"period":"ytd","weight":-0.0432}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"宁波健世科技股份有限公司是一家主要从事治疗结构性心脏病的介入产品及其他相关医疗产品研发的中国公司。该公司针对不同类型结构性心脏病，包括三尖瓣疾病、主动脉瓣疾病、二尖瓣疾病、心力衰竭及心源性卒中，开发一系列治疗解决方案。该公司的产品及管线主要包括LuX-Valve、LuX-Valve Plus、Ken-Valve、JensClip、JensRelive、MicroFlux和SimuLock。LuX-Valve是第一代经导管三尖瓣置换系统，为治疗有重度三尖瓣返流及高手术风险的患者而设计。Ken-Valve是第一代经导管主动脉瓣置换系统，为治疗重度主动脉瓣返流或合并主动脉瓣狭窄的患者而设计。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.136162},{"month":2,"riseRate":0.5,"avgChangeRate":0.00774},{"month":3,"riseRate":0.25,"avgChangeRate":-0.133402},{"month":4,"riseRate":0.5,"avgChangeRate":0.073914},{"month":5,"riseRate":0.25,"avgChangeRate":-0.008582},{"month":6,"riseRate":0.25,"avgChangeRate":-0.031042},{"month":7,"riseRate":0.5,"avgChangeRate":0.034573},{"month":8,"riseRate":0.5,"avgChangeRate":-0.087198},{"month":9,"riseRate":0.75,"avgChangeRate":0.102672},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.099341},{"month":11,"riseRate":0.5,"avgChangeRate":0.085892},{"month":12,"riseRate":0.75,"avgChangeRate":0.091534}],"exchange":"SEHK","name":"健世科技-B","nameEN":"JENSCARE-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"健世科技-B(09877)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供健世科技-B(09877)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"健世科技-B,09877,健世科技-B股票,健世科技-B股票老虎,健世科技-B股票老虎国际,健世科技-B行情,健世科技-B股票行情,健世科技-B股价,健世科技-B股市,健世科技-B股票价格,健世科技-B股票交易,健世科技-B股票购买,健世科技-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"健世科技-B(09877)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供健世科技-B(09877)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}